American Association for Cancer Research
00085472can202041-sup-245357_3_supp_6880639_qnpct2.docx (13.56 kB)

Supplementary Data from The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer

Download (13.56 kB)
journal contribution
posted on 2023-03-31, 04:20 authored by Anil Belur Nagaraj, Matthew Knarr, Sreeja Sekhar, R. Shae Connor, Peronne Joseph, Olga Kovalenko, Alexis Fleming, Arshia Surti, Elmar Nurmemmedov, Luca Beltrame, Sergio Marchini, Michael Kahn, Analisa DiFeo

Supplemental Table 1: Table of all antibodies used in studies including the company, catalog numbers and dilutions used to perform western blots.


Case Comprehensive Cancer Center

Rogel Cancer Center at the University of Michigan

National Cancer Institute

Department of Defense

CWRU Pharmacology Department MTTP Training grant



Wnt signaling is a major driver of stemness and chemoresistance in ovarian cancer, yet the genetic drivers that stimulate its expression remain largely unknown. Unlike other cancers, mutations in the Wnt pathway are not reported in high-grade serous ovarian cancer (HGSOC). Hence, a key challenge that must be addressed to develop effective targeted therapies is to identify nonmutational drivers of Wnt activation. Using an miRNA sensor-based approach, we have identified miR-181a as a novel driver of Wnt/β-catenin signaling. miR-181ahigh primary HGSOC cells exhibited increased Wnt/β-catenin signaling, which was associated with increased stem-cell frequency and platinum resistance. Consistent with these findings, inhibition of β-catenin decreased stem-like properties in miR-181ahigh cell populations and downregulated miR-181a. The Wnt inhibitor SFRP4 was identified as a novel target of miR-181a. Overall, our results demonstrate that miR-181a is a nonmutational activator of Wnt signaling that drives stemness and chemoresistance in HGSOC, suggesting that the miR–181a–SFRP4 axis can be evaluated as a novel biomarker for β-catenin–targeted therapy in this disease. These results demonstrate that miR-181a is an activator of Wnt signaling that drives stemness and chemoresistance in HGSOC and may be targeted therapeutically in recurrent disease.

Usage metrics

    Cancer Research





    Ref. manager